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Cutaneous Larva 
Migrans Acquired 
in Brittany, France
To the Editor: Hookworm-related 
cutaneous larva migrans is a parasitic 
dermatosis caused by the penetration 
of larvae, mostly of a dog or cat hook-
worm, into the epidermis of humans 
(1,2). This eruption is most commonly 
found in tropical and subtropical ar-
eas but was recently reported from 
western Europe, including Germany 
(3,4), England (5,6), Scotland (7), 
and southern France (8). We report a 
patient from the Netherlands who ac-
quired hookworm-related cutaneous 
larva migrans while on a holiday in 
Brittany, France.
A previously healthy 40-year-
old man from the Netherlands trav-
eled to Brittany, France, to visit from 
September 1 to September 15, 2008. 
He and his partner slept in tents, 
sometimes camping rough (not on 
designated camping sites or on pri-
vate property), and they stayed in 
low-budget hotels. They spent a lot 
of time on several beaches along the 
Atlantic Ocean on the southern shore 
of Brittany (≈48°N). The weather 
during their stay was variable. The 
patient was frequently bitten by mos-
quitoes, especially on his feet. He had 
not traveled to the tropics before and 
did not own any pets.
After his return to the Nether-
lands, the area around 2 presumed 
mosquito bites at the lateral side of 
his right foot became red, swollen, 
and itchy. This area evolved into a 
1-cm pustule that later turned into a 
bulla. On November 10, he visited 
his general practitioner, who made a 
diagnosis of cellulitis and started the 
patient on amoxicillin/clavulanic acid 
625 mg, 3×/day for 10 days. During 
antimicrobial drug treatment, skin in-
fl ammation improved, but after 2 days 
the patient noticed that an itching red 
streak had developed, extending from 
the lesions on the lateral side of the 
right foot to the whole width of the 
sole of the foot. The tip of the streak 
proceeded along the sole of the foot 
at the rate of 2 cm/day. On the fi fth 
day, he was referred to our Tropical 
Diseases outpatient clinic.
Physical examination showed 
2 elevated, ulcerative lesions on the 
lateral side of the right foot, and from 
each originated an elevated serpigi-
nous lesion (Figure, panels B and C). 
These were typical tortuous lesions 
2 cm in width. One of the lesions ran 
across the whole sole of the right foot 
and was 14 cm in length (Figure, pan-
els A and C). The medial end of the 
lesion was fervently erythematous. 
Based on clinical signs, we diagnosed 
the skin lesion as hookworm-related 
cutaneous larva migrans with second-
ary impetiginization. The patient was 
subsequently treated with a single oral 
dose of 12 mg ivermectin. The itch 
and the progression of the lesion halt-
ed instantly and the lesion disappeared 
during the following weeks. The larva 
was not extirpated and thus not further 
identifi ed.
Hookworm-related cutaneous 
larva migrans is usually caused by An-
cylostoma brasiliense, A. caninum or, 
rarely, Uncinaria stenocephala. These 
zoonotic hookworms need a high tem-
perature and a moist environment to 
develop from an embryo to fi lariforme 
larva (1,2). Hookworm-related cuta-
neous larva migrans is typically a dis-
order of tropical and subtropical zones 
and it is rather common among tourists 
who visit tropical beaches. This was 
the fi rst patient we had seen with this 
disease who became infected in west-
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ern Europe. Apart from an exception-
ally hot day on August 30 (maximum 
26°C), the weather was not particu-
larly warm during the summer of 2008 
in Brittany; during the fi rst 2 weeks of 
September the average minimum and 
maximum temperatures were 11°C 
and 17°C, respectively. Rainfall was 
moderate and humidity was ≈86% (9). 
However, the overall warmer climate, 
including warmer winters, might have 
created the conditions for zoonotic 
hookworm infections in humans in 
western Europe (10).
Our patient may have been in-
fected by U. stenocephala, a nematode 
of dogs that is common in temperate 
zones but rarely causes hookworm-
related cutaneous larva migrans. An 
increase in ambient temperature might 
increase the incidence of these zoonot-
ic infections in northern regions. Only 
4 cases of hookworm-related cutane-
ous larva migrans were previously 
reported in France, all from south-
ern regions (8). A northern spread of 
hookworm-related cutaneous larva 
migrans could thus point to expansion 
of the global distribution of the more 
tropical hookworms or altered condi-
tions that favor the emergence of in-
fection by a zoonotic hookworm such 
as U. stenocephala. Either explanation 
calls for screening of infection in cats 
and dogs and preventing pet animals 
and possibly stray animals from ac-
cessing beaches. Clinicians should be 
aware of the possibility of hookworm-
related cutaneous larva migrans in 
patients who have traveled to western 
Europe and, in particular, those who 
have stayed on the beaches.
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Figure. Right foot of a patient from Brittany, France, with a hookworm-related cutaneous 
larva migrans, showing an elevated serpiginous lesion on the sole of the foot (panels A, B) 
and ulcerative lesions at the origin of the lesions on the lateral side of the foot (panel C). 
A color version of this fi gure is available online (www.cdc.gov/EID/content/15/11/1856-F.
htm).
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European 
Perspective of 
2-Person Rule for 
Biosafety Level 4 
Laboratories
To the Editor: Recently, the di-
rectors of Biosafety Level 4 (BSL-4) 
laboratories in the United States pub-
lished their views of the requirement 
of having ≥2 persons present at all 
times while biological work is under-
taken in a BSL-4 laboratory (1). They 
concluded that safety and security 
would be better assured in some situ-
ations by video monitoring systems 
rather than by the presence of a fellow 
scientist. As members of the European 
Network of Biosafety Level-4 labo-
ratories (Euronet-P4) who have de-
veloped guidelines in this area (2–4), 
we discussed the article during a re-
cent network meeting. Biosafety and 
biosecurity are the major concerns 
for all involved in BSL-4 activities, 
and we support the authors’ initiative 
and broadly agree with their posi-
tion. The consensus among European 
BSL-4 experts is that, in the interest of 
safety, standard practice should be for 
all laboratories to perform a risk as-
sessment before any activity is under-
taken. This preliminary assessment is 
the best way to determine procedures 
to be used, including whether 2 per-
sons should work together as part of 
laboratory procedure. A 2-person rule 
is inappropriate simply because the 
best approach is not to have infl exible 
rules that are not objectively assessed 
according to laboratory-specifi c cir-
cumstances.
Surveillance video monitoring 
and data storing have their place in 
protecting laboratory facilities from 
unauthorized access and theft of ma-
terials, but their effectiveness for en-
suring proper handling of pathogens 
is quite limited. Finally, we agree with 
the authors that both biosafety and 
biosecurity must be founded on care-
ful selection and monitoring of staff, 
without which even the most sophisti-
cated of control systems would fail.
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Multidrug-Resistant 
Mycobacterium 
tuberculosis Strain 
from Equatorial 
Guinea Detected 
in Spain
To the Editor: Eleven years of 
molecular epidemiologic data allowed 
the Spanish Multidrug-resistant Tu-
berculosis (MDR TB) Surveillance 
Network to identify a specifi c MDR 
Mycobacterium tuberculosis strain 
that had been imported into Spain 
from Equatorial Guinea (1). Our study 
brings to light the potential dissemi-
nation of this strain (named MDR-
TBEG) in Equatorial Guinea, a coun-
try where little is known about the 
extent and features of TB or MDR TB. 
It also highlights that MDR strains 
can spread across continents, and thus 
MDR TB’s emergence in any country 
becomes a global problem.
Ten MDR M. tuberculosis isolates 
obtained from 10 patients from Equa-
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